Clinical Trial Update: Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Efavaleukin Alfa for active systemic lupus erythematosus was terminated, with efficacy and safety results posted in June 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Efavaleukin Alfa (efavaleukin alfa)

Snippet

Sponsor: Amgen | Conditions: Active Systemic Lupus Erythematosus | Phase 2 | Status: TERMINATED | Results posted: 2024-06-28